PD-1/PD-L1
PD-1/Programmed death-ligand 1
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.
PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.
All Product Categories
-
PD-1/PD-L1 Inhibitors
(344)
View all products
-
PD-1/PD-L1 Agonists
(5)
View all products
-
PD-1/PD-L1 Antagonists
(11)
View all products
-
PD-1/PD-L1 Activators
(16)
View all products
-
PD-1/PD-L1 Modulators
(7)
View all products
-
PD-1/PD-L1 Inducers
(3)
View all products
-
PD-1/PD-L1 Degraders
(13)
View all products
-
PD-1/PD-L1 Control
(1)
View all products
-
PD-1/PD-L1 Substrates
(2)
View all products
-
PD-1/PD-L1 Ligands
(7)
View all products
-
PD-1/PD-L1 Related Products (454)
Related Products (454)
-
Antibodies (8)
-
TY101
0 ImagesCat. No.: HY-P992478TY101 is an anti-PDCD1/PD-1/CD279 monoclonal antibody. TY101 binds to and inhibits PD-1 and its downstream signaling pathways.
-
PD-1/PD-L1-IN-64
0 ImagesCat. No.: HY-183775CAS No.: 3114769-08-0PD-1/PD-L1-IN-64 is a PD-1/PD-L1 interaction inhibitor. PD-1/PD-L1-IN-64 induces PD-L1 internalization and oligomerization, enhances T-cell activation, proliferation, and cancer cell elimination. PD-1/PD-L1-IN-64 can be used for the research of cancer.
-
STI-1110
0 ImagesCat. No.: HY-P992468STI-1110 is a human monoclonal antibody targeting PD-1, which can be used in cancer-related research.
-
DK 221
0 ImagesCat. No.: HY-P11888CAS No.: 1886065-39-9
-
ABM101
0 ImagesCat. No.: HY-P992168ABM101 is a humanized monoclonal antibody targeting PD-L1.
-
CC-90006
0 ImagesCat. No.: HY-P991346
-
PD-1/PD-L1-IN-39
0 ImagesCat. No.: HY-163307CAS No.: 3032270-35-9PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with a IC50 value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with KD values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity.
-
PDL-GEX
0 ImagesCat. No.: HY-P991355PDL-GEX is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. PDL-GEX can be used in cancer research.
-
Cadapersen sodium
0 ImagesCat. No.: HY-177620ASynonyms: RG6084 sodium; RO-7191863 sodiumCadapersen sodium is an antisense oligonucleotide that induces the degradation of PD-L1 mRNA. It is used for the study of chronic hepatitis B (CHB).
-
PD-1/PD-L1-IN-27
0 ImagesCat. No.: HY-146740CAS No.: 2891831-47-1PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8+ T cells and reduces T cell exhaustion.
-
PD-1/PD-L1-IN-47
0 ImagesCat. No.: HY-159125CAS No.: 1137341-95-7PD-1/PD-L1-IN-47 (MolPort-001-742-690) is a PH-selective PD-1/PD-L1 signaling pathway inhibitor with significant affinity for PD-L1 under acidic conditions and lower toxicity. PD-1/PD-L1-IN-47 can be used in the study of tumors.
-
N2S2-CBMBC
0 ImagesCat. No.: HY-145769CAS No.: 2547100-02-5N2S2-CBMBC, an N2S2 bromo-benzyl ether derivative, acts as a ligand and use 99mTc-labelled complexes 99mTc-N2S2-CBMBC can be used as an imaging agent to be applied to the aspect of detecting PD-L1 expression, realize the real-time, comprehensive and convenient detection of the PD-L1 level of tumors, and overcome the defects of an immunohistochemical method.
-
CSN5-IN-3
0 ImagesCat. No.: HY-181795CSN5-IN-3 (Compound 30) is a CSN5 inhibitor with an IC50 of 0.58 μM. CSN5-IN-3 inhibits the enzymatic activity of CSN5, leading to increased accumulation of NEDD8-Cul1 and promoting the degradation of PD-L1. CSN5-IN-3 downregulates Bcl-2, and upregulates P53 and Cleaved caspase-3. CSN5-IN-3 exhibits anticancer activity against triple-negative breast cancer.
-
Acesulfame potassium (Standard)
0 ImagesAcesulfame potassium (Standard) is the analytical standard of Acesulfame potassium (HY-D0195). This product is intended for research and analytical applications. Acesulfame potassium is a synthetic sweetener. Long-term use of Acesulfame potassium can affect cognitive function, possibly by altering the neurometabolic functions in mice. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame potassium can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion.
-
PD-L1-IN-6
0 ImagesCat. No.: HY-162399PD-L1-IN-6 (Compound 16) is an orally active inhibitor for PD-L1 expression in neutrophil by targeting STAT3 with KD of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse.
-
PD-1/PD-L1-IN-50
0 ImagesCat. No.: HY-168078CAS No.: 3061401-24-6PD-1/PD-L1-IN-50 (Compound LG-12) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + T cell activation, and activates the antitumor immunity of T cells.
-
SWS1
0 ImagesCat. No.: HY-155681CAS No.: 2922115-32-8SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%).
-
PD-L1/HDAC6-IN-1
0 ImagesCat. No.: HY-172200CAS No.: 2834094-36-7PD-L1/HDAC6-IN-1 is an orally active dual inhibitor of PD-L1 and HDAC6, with IC50 values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma.
-
PD-1/PD-L1-IN-68
0 ImagesCat. No.: HY-187712CAS No.: 3056281-16-1PD-1/PD-L1-IN-68 is a PD-L1 inhibitor based on a tetrahydroisoquinoline scaffold, with a KD of 21.31 μM for binding to hPD-L1, and it blocks the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-68 restores T cell immune function, thereby promoting the death of PD-L1+ cancer cells. PD-1/PD-L1-IN-68 can be used in studies related to liver cancer.
